SCHEMBL1780035

SCHEMBL1780035

CCOC(=O)n1nc(NC(=O)c2ccccc2NC(=O)c2cc(C)[nH]n2)c2cc(C(=O)NC(C)(C)c3ccccc3F)sc21

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MAPT P10636 5/20 0.36
TP53 P04637 3/20 0.36
HSD17B10 Q99714 4/20 0.35
ALDH1A1 P00352 4/20 0.35
GAA P10253 4/20 0.35
KDM4E B2RXH2 3/20 0.35
MAPK1 P28482 2/20 0.35
MEN1 O00255 2/20 0.35
NPSR1 Q6W5P4 2/20 0.33
LMNA P02545 2/20 0.33
PPARG P37231 1/20 0.33
NR1H4 Q96RI1 1/20 0.33
TSHR P16473 2/20 0.33
GLA P06280 1/20 0.32
CREBBP Q92793 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1779428 0.91 ABL1 (0.40) KMT2ASMN1; SMN2MAPTTP53HSD17B10
SCHEMBL1777980 0.89 AURKA (0.40) KMT2AHSD17B10ALDH1A1GAAKDM4E
SCHEMBL1778745 0.87 HSD17B10 (0.35) KMT2ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL1781046 0.86 ALDH1A1 (0.38) KMT2ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL1778410 0.86 ALDH1A1 (0.40) KMT2ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL1777881 0.86 HSD17B10 (0.35) KMT2ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL1779165 0.86 KDM4E (0.38) KMT2ASMN1; SMN2RAB9AMAPTTP53
SCHEMBL1779872 0.85 KDR (0.37) KMT2ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL1780516 0.85 KDM4E (0.38) KMT2ASMN1; SMN2NPC1RAB9AMAPT
SCHEMBL1779178 0.83 MEN1 (0.38) KMT2ASMN1; SMN2MAPTTP53HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 KMT2A 2397/4885SMN1; SMN2 4365/4885NPC1 2677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.